UNITED KINGDOM: Benchmark Holdings has developed specific pathogen resistant (SPR) shrimp to address issues facing the Asian market and has plans to soon commence field trials in the region.
This breakthrough development, which is the result of over 20 years experience in the firm’s breeding and genetics teams in Norway and Colombia, aims at avoiding losses, valued at billions of dollars per year for the global shrimp industry, due to disease.
Benchmark's SPR shrimp have proven resistance to major diseases including white spot, taura (TSV), NHP (necrotising hepatopancreatitis), IHHNV and vibriosis.
“We are now turning to the commercialisation phase of this technology taking it into the major shrimp production markets around the world, " pointed out Malcolm Pye, Benchmark’s CEO.
"It's an example of where you can apply modern technology to an industry challenged with major problems to create a breakout moment and resolve some of the fundamental issues that they are facing. We have been able to trapercentnsfer the insights we learned from salmon genetics to shrimp. Shrimp is ideal for a genetic breeding program because of the size of the market, the short cycle and their high reproductive capacity," the executive added.
Asia produces more than 2.66 million tonnes of vannamei shrimp, worth around USD 13 billion annually, with the total value of the market growing by an average 7 percent each year.